[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alixer Nexgen Therapeutics Limited\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100609843","phase-2-a-study-to-determine-the-optimal-dose-and-frequency-of-aldp001-nasal-spray-in-adults-with-seasonal-allergic-rhinitis-under-allergen-exposure-100609843",false,"NCT07219849","A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure","A Two-part Adaptive Double-blind Randomized Placebo-controlled Study to Assess the Appropriate Dose and the Appropriate Dosing Frequency of ALDP 001 in Adults With Seasonal Allergic Rhinitis (SAR) Assessed Using an Allergen Challenge Chamber\u002FEEC","ALDP001","Inclusion Criteria:\n\n* Diagnosis of Allergic Rhinitis (AR), as determined by the presence of seasonal rhinitis symptoms for several months per year, for more than 1 year and are not attributed to infections or nasal abnormalities\n* Positive skin prick test (SPT) response to ragweed pollen (allergen induced wheal diameter at least 3 mm larger than the negative control) in the previous 12 months\n* Healthy as determined by a responsible and experienced Investigator, based on a medical evaluation including medical history, physical examination, vital signs, ECG, and lab tests.\n\nExclusion Criteria:\n\n* Nasal abnormalities likely to affect the outcome of the study, i.e. nasal septal perforation, nasal polyps, sinusitis and other nasal malformations.\n* History of frequent nosebleeds.\n* Participants with rhinitis medicamentosa.\n* Current or chronic history of hepatic disease.\n* A QTcF (Fridericia-corrected QT interval) \\>450 ms in males or \\>470 ms in females.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},164,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.",[29],"Seasonal Allergic Rhinitis (SAR)",[31],"ALDP001 Nasal Spray","RECRUITING","2025-10-21",{"date":35,"type":36},"2025-10-22","ACTUAL",{"date":38,"type":36},"2025-10-17",{"date":40,"type":23},"2026-04",{"name":42,"class":43},"Alixer Nexgen Therapeutics Limited","INDUSTRY",""]